BioMark Diagnostics Inc.
BUX.CN
Get informed when a big investor buys or sells
+ FollowMarket Cap$55.7M
Close$
$-0.03
105% downside
Current Fair Value
105% downsideOvervalued by 105% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $55.70 Million |
|---|---|
| Enterprise Value | $56.24 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.01 |
| Beta | -0.32 |
| Outstanding Shares | 106,357,472 |
Return
| Return on Equity | -249.56% |
|---|---|
| Return on Assets | -65.79% |
| Return on Invested Capital | -123.67% |
Valuation & Multiples
| P/E Ratio | -39.26 |
|---|---|
| PEG | 315.88 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 2022.78 |
| Enterprise Value to EBIT | -30.34 |
| Enterprise Value to Net Income | -40 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 2.23 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About BioMark Diagnostics Inc.
9 employees
CEO: Rashid Ahmed Maula Bux BioMark Diagnostics Inc. is an oncology-focused firm that develops sophisticated diagnostic tools for cancer. These solutions are designed to aid in the identification of the disease, its ongoing monitoring, and the assessment of initial...